BioSpace News Archive

Following a record first half year, sales weakened in the third quarter. However, the market situation and demand for our products remain favorable and we have confidence in our strategy

Since the US is the world’s largest market for neurosurgical procedures, we have focused much of our team’s resources toward supporting a successful early market introduction.

Statins are an effective medication for treating patients with heart disease – they cut the risk of a second major adverse cardiac event by almost 50 percent.

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, announced the pricing of its public offering of 3,678,031 shares of its common stock at a public offering price of $13.61 per share.

Cerecor Inc. announced its financial results for the third quarter ended September 30, 2019 and provided additional corporate highlights.

AstraZeneca and Merck’s Selumetinib Would Become the First Medicine Indicated for the Treatment of Certain Pediatric Patients with NF1 Plexiform Neurofibromas if Approved

Stealth BioTherapeutics Corp. reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.

Data from the phase 1b study of ALX148, a CD47 blocker with an engineered inactive Fc domain, in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma will be presented on December 7

Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones

CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting with investors at Piper Jaffray’s 31st Annual Healthcare Conference